Quratis 
Welcome,         Profile    Billing    Logout  
  Products    Diseases   Products    Trials    News 
4 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Gemcovac (HDT-301) / HDT Bio Corp, Emcure
NCT05542693: Safety and Immunogenicity of the RNA MCTI CIMATEC HDT Vaccine

Not yet recruiting
2b
300
NA
RNA MCTI CIMATEC HDT 5µg, RNA MCTI CIMATEC HDT 10µg, Covishield® - AstraZeneca, Comirnaty® - Pfizer
Azidus Brasil, SENAI CIMATEC
COVID-19, COVID-19 Vaccine
03/23
09/23
NCT05876364: Study to Assess Safety, Reactogenicity and Immunogenicity of the repRNA(QTP104) Vaccine Against SARS-CoV-2(COVID-19)

Active, not recruiting
1
36
RoW
QTP104 1ug, QTP104 5ug, QTP104 25ug
Quratis Inc.
COVID-19, SARS-CoV-2
06/22
08/23
NCT04844268: Study to Assess Safety, Reactogenicity and Immunogenicity of the VACCINE RNA MCTI CIMATEC HDT (HDT-301) Vaccine Against COVID-19

Recruiting
1
90
RoW
Cohort 1 VACCINE RNA MCTI CIMATEC HDT (HDT-301) vaccine, Cohort 2 RNA VACCINE MCTI CIMATEC HDT(HDT-301) vaccine, Cohort 3 VACCINE RNA MCTI CIMATEC HDT(HDT-301) vaccine, Placebo
SENAI CIMATEC
SARS-CoV-2
09/22
10/22
HDT-301-002, NCT05132907: Safety and Immunogenicity of HDT-301 Targeting a SARS-CoV-2 Variant Spike Protein

Completed
1
48
US
HDT-301
HDT Bio, Rainier Clinical Research Center, C3 Research Associates
SARS-CoV2 Infection
11/23
05/24

Download Options